Retrieve available abstracts of 87 articles: HTML format
Single Articles
June 2025
PASSIGLIA F, Pepe F, Russo G, Garbo E, et al Circulating tumor DNA dynamic variation predicts sotorasib efficacy in
KRASp.G12C-mutated advanced non-small cell lung cancer.
Cancer. 2025;131:e35917. PubMedAbstract available
May 2025
DENNEHY C, Conroy MR, Forde PM Immunotherapy for resectable lung cancer.
Cancer. 2025;131:e35849. PubMedAbstract available
KILICKAP S, Ozguroglu M, Sezer A, Gumus M, et al Cemiplimab monotherapy as first-line treatment of patients with brain metastases
from advanced non-small cell lung cancer with programmed cell death-ligand 1 >/=50.
Cancer. 2025;131:e35864. PubMedAbstract available
HOFF CO, Feng L, Bonini F, Sousa LG, et al Survival outcomes of pulmonary metastasis-directed local therapy in adenoid
cystic carcinoma.
Cancer. 2025;131:e35901. PubMedAbstract available
SHOU J, Chen J, Guo Q, Hong W, et al Anlotinib in combination with docetaxel for advanced nonsmall cell lung cancer
after failure of platinum-based treatment: A phase 1/2 trial.
Cancer. 2025;131:e35822. PubMedAbstract available
GARG SK, Kohli K, Garg IK, Garg YK, et al Disparities in receipt of palliative-intent treatment among disaggregated
Hispanic populations with breast, lung, and prostate cancer in the United States.
Cancer. 2025;131:e35903. PubMedAbstract available
HARRIS AK, Nelson AT, Watson D, Mallinger PHR, et al Ovarian juvenile granulosa cell tumor: A report from the International Ovarian
and Testicular Stromal Tumor and International Pleuropulmonary Blastoma/DICER1
Registries.
Cancer. 2025;131:e35862. PubMedAbstract available
THOMAS QD, Vendrell JA, Khellaf L, Cavaillon S, et al Artificial intelligence-driven microsatellite instability profiling reveals
distinctive genetic features in patients with lung cancer.
Cancer. 2025;131:e35882. PubMedAbstract available
April 2025
MACHIDA N, Okumura T, Boku N, Kishimoto J, et al A phase 2 study of adjuvant chemotherapy with 5-fluorouracil/leucovorin and
oxaliplatin after lung metastasectomy for colorectal cancer (WJOG5810G).
Cancer. 2025;131:e35807. PubMedAbstract available
March 2025
SHIELDS MD, Chiang AC, Byers LA Top advances of the year: Small cell lung cancer.
Cancer. 2025;131:e35770. PubMedAbstract available
BOGDANSKA W, Paik PK From knowledge to action: The journey toward targeting the MET pathway via MET
exon 14 skipping.
Cancer. 2025;131 Suppl 1:e35782. PubMedAbstract available
JIMENEZ MUNARRIZ BE, Khan S, Li Y, Ghazali N, et al Update advances in anaplastic lymphoma kinase-positive non-small cell lung cancer
treatment.
Cancer. 2025;131 Suppl 1:e35786. PubMedAbstract available
SHAVERDASHVILI K, Burns TF Advances in the treatment of KRAS(G12C) mutant non-small cell lung cancer.
Cancer. 2025;131 Suppl 1:e35783. PubMedAbstract available
PARISI C, Planchard D BRAF in non-small cell lung cancer: From molecular mechanisms to clinical
practice.
Cancer. 2025;131 Suppl 1:e35781. PubMedAbstract available
HOE HJ, Solomon BJ Treatment of non-small cell lung cancer with RET rearrangements.
Cancer. 2025;131 Suppl 1:e35779. PubMedAbstract available
KIM J, Park S, Ku BM, Ahn MJ, et al Updates on the treatment of epidermal growth factor receptor-mutant non-small
cell lung cancer.
Cancer. 2025;131 Suppl 1:e35778. PubMedAbstract available
REINHORN D, Moskovitz M, Tap WD, Li BT, et al Targeting HER2 in lung cancers: Evolving treatment landscape and drug development
strategies.
Cancer. 2025;131 Suppl 1:e35780. PubMedAbstract available
DESILETS A, Repetto M, Yang SR, Drilon A, et al Targeting ROS1 rearrangements in non-small cell lung cancer: Current insights and
future directions.
Cancer. 2025;131 Suppl 1:e35784. PubMedAbstract available
February 2025
SANDS JM, Champiat S, Hummel HD, Paulson KG, et al Practical management of adverse events in patients receiving tarlatamab, a
delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for
previously treated small cell lung cancer.
Cancer. 2025;131:e35738. PubMedAbstract available
January 2025
NIERENGARTEN MB First person profile: Julie Brahmer, MD: Dr Brahmer's research paved the way for
the first immunotherapy agent to receive US Food and Drug Administration approval
for the treatment of lung cancer.
Cancer. 2025;131:e35686. PubMed
PASSMAN JE, Kallan MJ, Roberson JL, Ginzberg SP, et al Contemporary trends in utilization of metastasectomy in the era of targeted and
immunotherapies.
Cancer. 2025;131:e35664. PubMedAbstract available
GANTI AK, Fruth B, Rimner A, Waqar S, et al Quality of life outcomes in patients participating in the CALGB 30610 trial
(CALGB 70702): Alliance.
Cancer. 2025;131:e35663. PubMedAbstract available
MCCOLL KS, Ajay A, Wang H, Wildey GM, et al Identification of HEPACAM2 as a novel and specific marker of small cell
carcinoma.
Cancer. 2025;131:e35557. PubMedAbstract available
December 2024
POTTER AL, Kuhan S, Senthil P, Mansur A, et al The 2021 US Preventive Services Task Force lung cancer screening eligibility
criteria disproportionately exclude younger Black patients with lung cancer.
Cancer. 2024 Dec 11. doi: 10.1002/cncr.35676. PubMedAbstract available
ZHANG D, Rohatgi A Improving survival for patients with metastatic non-small cell lung cancer in the
immunotherapy era.
Cancer. 2024 Dec 11. doi: 10.1002/cncr.35675. PubMed
November 2024
DESAI P, Zhou Y, Grenet J, Handelman SK, et al Association of clonal hematopoiesis and mosaic chromosomal alterations with solid
malignancy incidence and mortality.
Cancer. 2024;130:3879-3887. PubMedAbstract available
October 2024
NIERENGARTEN MB Durvalumab not cost-effective with current pricing strategies for stage III
NSCLC: The drug remains inaccessible to many patients for whom it is indicated as
a standard of care after chemoradiation.
Cancer. 2024;130:3236. PubMed
September 2024
FOX AH, Osarogiagbon RU, Farjah F, Jett JR, et al The American Cancer Society National Lung Cancer Roundtable strategic plan:
Advancing comprehensive biomarker testing in non-small cell lung cancer.
Cancer. 2024 Sep 30. doi: 10.1002/cncr.34628. PubMedAbstract available
FARJAH F, Barta JA, Wood DE, Rivera MP, et al The American Cancer Society National Lung Cancer Roundtable strategic plan:
Promoting guideline-concordant lung cancer staging.
Cancer. 2024 Sep 30. doi: 10.1002/cncr.34627. PubMedAbstract available
ROY-CHOWDHURI S, Mani H, Fox AH, Tsao A, et al The American Cancer Society National Lung Cancer Roundtable strategic plan:
Methods for improving turnaround time of comprehensive biomarker testing in
non-small cell lung cancer.
Cancer. 2024 Sep 30. doi: 10.1002/cncr.34926. PubMedAbstract available
BARTA JA, Farjah F, Thomson CC, Dyer DS, et al The American Cancer Society National Lung Cancer Roundtable strategic plan:
Optimizing strategies for lung nodule evaluation and management.
Cancer. 2024 Sep 30. doi: 10.1002/cncr.35181. PubMedAbstract available
BACKHUS LM, Chang CF, Sakoda LC, Chambers SR, et al The American Cancer Society National Lung Cancer Roundtable strategic plan: Lung
cancer in women.
Cancer. 2024 Sep 20. doi: 10.1002/cncr.35083. PubMedAbstract available
FATHI JT, Barry AM, Greenburg GM, Henschke CI, et al The American Cancer Society National Lung Cancer Roundtable strategic plan:
Implementation of high-quality lung cancer screening.
Cancer. 2024 Sep 20. doi: 10.1002/cncr.34621. PubMedAbstract available
LEWIS JA, Klein DE, Eberth JM, Carter-Bawa L, et al The American Cancer Society National Lung Cancer Roundtable strategic plan:
Provider engagement and outreach.
Cancer. 2024 Sep 20. doi: 10.1002/cncr.34555. PubMedAbstract available
VOLK RJ, Myers RE, Arenberg D, Caverly TJ, et al The American Cancer Society National Lung Cancer Roundtable strategic plan:
Current challenges and future directions for shared decision making for lung
cancer screening.
Cancer. 2024 Sep 20. doi: 10.1002/cncr.35382. PubMedAbstract available
KAZEROONI EA, Wood DE, Rosenthal LS, Smith RA, et al The American Cancer Society National Lung Cancer Roundtable strategic plan:
Introduction.
Cancer. 2024 Sep 20. doi: 10.1002/cncr.35385. PubMedAbstract available
NIERENGARTEN MB ASCO 2024: Advances in lung cancer treatments and care: A new standard of care
therapy based on the results of the LAURA study underscores the need for testing
for epidermal growth factor receptor (EGFR) mutations in patients with
unresectable stage I
Cancer. 2024;130:2894. PubMed
August 2024
NIERENGARTEN MB First person profile: Heather A. Wakelee, MD: For more than 20 years, she has
served in multiple functions, including developing research programs in lung
cancer and thymoma that include clinical trials and population science
approaches.
Cancer. 2024;130:2730. PubMed
BEATRICI E, Paciotti M, Nguyen DD, Filipas DK, et al Estimating the impact of enhanced care at minority-serving hospitals on
disparities in the treatment of breast, prostate, lung, and colon cancers.
Cancer. 2024;130:2770-2781. PubMedAbstract available
July 2024
WANG Y, Kondrat K, Adhikari J, Nguyen Q, et al Survival trends among patients with metastatic non-small cell lung cancer before
and after the approval of immunotherapy in the United States: A Surveillance,
Epidemiology, and End Results database-based study.
Cancer. 2024 Jul 10. doi: 10.1002/cncr.35476. PubMedAbstract available
June 2024
CHO H, Kwon H, Kim SH, Ahn HM, et al Seasonal influences on the efficacy of anti-programmed cell death (ligand) 1
inhibitors in lung cancer.
Cancer. 2024 Jun 28. doi: 10.1002/cncr.35454. PubMedAbstract available
MAKAREM M, Janne PA Top advances of the year: Targeted therapy for lung cancer.
Cancer. 2024 Jun 21. doi: 10.1002/cncr.35423. PubMedAbstract available
YABROFF KR, Mittu K, Halpern MT Cost-of-care discussions for individuals with advanced non-small cell lung cancer
and melanoma: Findings from a large, population-based pilot study.
Cancer. 2024 Jun 13. doi: 10.1002/cncr.35380. PubMedAbstract available
EDWARDS DM, Pirzadeh M, Van T, Jiang R, et al Impact of lung cancer screening on stage migration and mortality among the
national Veterans Health Administration population with lung cancer.
Cancer. 2024 Jun 10. doi: 10.1002/cncr.35340. PubMedAbstract available
BYUN JY, Aiyeolemi A, Qdaisat A, Park C, et al Association between epidermal growth factor receptor-tyrosine kinase inhibitors
and venous thromboembolism among older patients with advanced non-small cell lung
cancer.
Cancer. 2024 Jun 7. doi: 10.1002/cncr.35424. PubMedAbstract available
May 2024
AREDO JV, Wakelee HA Top advances of the year: Perioperative therapy for lung cancer.
Cancer. 2024 May 8. doi: 10.1002/cncr.35357. PubMedAbstract available
LEAL TA, Ramalingam SS Commemorating the 20th anniversary of the discovery of epidermal growth factor
receptor mutation in lung cancer: Translational research at its best.
Cancer. 2024 May 8. doi: 10.1002/cncr.35353. PubMed
YOUNG LK, Halmos B Immunotherapy for metastatic non-small cell lung cancer: Is it really a
no-brainer?
Cancer. 2024 May 6. doi: 10.1002/cncr.35350. PubMed
April 2024
AJABNOOR AM, Parisi R, Zghebi SS, Ashcroft DM, et al Oral anticoagulant prescribing among patients with cancer and atrial fibrillation
in England, 2009-2019.
Cancer. 2024;130:1316-1329. PubMedAbstract available
March 2024
VITA E, Monaca F, Milardi D, Mastrantoni L, et al Symptomatic androgen deficiency and sexual dysfunctions in male patients
receiving alectinib for ALK-positive advanced nonsmall cell lung cancer.
Cancer. 2024 Mar 28. doi: 10.1002/cncr.35293. PubMedAbstract available
WISNIVESKY JP, Mudd J, Stone K, Slatore CG, et al Longitudinal quality of life after sublobar resection and stereotactic body
radiation therapy for early-stage non-small cell lung cancer.
Cancer. 2024 Mar 21. doi: 10.1002/cncr.35286. PubMedAbstract available
CITTOLIN-SANTOS GF, Knapp B, Ganesh B, Gao F, et al The changing landscape of small cell lung cancer.
Cancer. 2024 Mar 12. doi: 10.1002/cncr.35281. PubMedAbstract available
NIERENGARTEN MB Updated American Cancer Society lung cancer screening guidelines: The new
guidelines offer expanded criteria recommended for lung cancer screening based on
age, smoking status, and smoking history.
Cancer. 2024;130:656-657. PubMed
WEST HJ, Pennell NA Lessons from ADAURA: Can we improve on a positive trial?
Cancer. 2024;130:659-664. PubMed
February 2024
TAN AC, Lai GGY, Saw SPL, Chua KLM, et al Detection of circulating tumor DNA with ultradeep sequencing of plasma cell-free
DNA for monitoring minimal residual disease and early detection of recurrence in
early-stage lung cancer.
Cancer. 2024 Feb 29. doi: 10.1002/cncr.35263. PubMedAbstract available
MORGENSZTERN D The expanding role of circulating tumor DNA in resectable non-small cell lung
cancer.
Cancer. 2024 Feb 29. doi: 10.1002/cncr.35268. PubMed
Erratum to "Patient-reported outcomes with cemiplimab monotherapy for first-line
treatment of advanced non-small cell lung cancer with PD-L1 of >/=50%: The
EMPOWER-Lung 1 study".
Cancer. 2024 Feb 23. doi: 10.1002/cncr.35165. PubMed
NIERENGARTEN MB Phase 3 AEGEAN trial results show the benefit of perioperative
immunotherapy-based treatment for NSCLC.
Cancer. 2024;130:495-496. PubMed
DESAI A, Smith CJ, Pritchett JC, Leventakos K, et al Examining crossover and postprotocol therapies in first-line immunotherapy trials
in non-small cell lung cancer (NSCLC).
Cancer. 2024 Feb 14. doi: 10.1002/cncr.35250. PubMedAbstract available
ZHOU Y, Guo T, Liang F, Wang Z, et al Cumulative incidence and risk factors of brain metastases in metastatic non-small
cell lung cancer without baseline brain metastasis: Pooled analysis of
individualized patient data from IMpower130, IMpower131, and IMpower150.
Cancer. 2024 Feb 14. doi: 10.1002/cncr.35242. PubMedAbstract available
RUSSELL AM, Pack AP, Bailey SC, Weldon CB, et al A local perspective on internal, external, and reflexive biomarker testing
processes for lung cancer in an academic medical center.
Cancer. 2024 Feb 14. doi: 10.1002/cncr.35240. PubMed
January 2024
IOCOLANO M, Yegya-Raman N, Friedes C, Wang X, et al Acute hospitalizations after proton therapy versus intensity-modulated
radiotherapy for locally advanced non-small cell lung cancer in the durvalumab
era.
Cancer. 2024 Jan 31. doi: 10.1002/cncr.35230. PubMedAbstract available
FLOREZ N, Kaufman RA, Yanez-Sarmiento A, Abioye O, et al When the unimaginable happens: Lung cancer diagnosis during pregnancy.
Cancer. 2024 Jan 29. doi: 10.1002/cncr.35227. PubMed
BYRD DA, Zouiouich S, Karwa S, Li XS, et al Associations of serum trimethylamine N-oxide and its precursors with colorectal
cancer risk in the Prostate, Lung, Colorectal, Ovarian Cancer Screening Trial
Cohort.
Cancer. 2024 Jan 29. doi: 10.1002/cncr.35219. PubMedAbstract available
KRATZER TB, Bandi P, Freedman ND, Smith RA, et al Lung cancer statistics, 2023.
Cancer. 2024 Jan 27. doi: 10.1002/cncr.35128. PubMedAbstract available
ROLFO C, Del Re M, Russo A Exploring the epigenetic susceptibility mechanisms of lung cancer through DNA
methylation markers.
Cancer. 2024 Jan 18. doi: 10.1002/cncr.35203. PubMed
HONG J, Lee J, Park S, Jung HA, et al Immune checkpoint inhibitor use and the incidence of hepatitis B virus
reactivation or immune-related hepatitis in non-small cell lung cancer patients
with chronic hepatitis B.
Cancer. 2024 Jan 2. doi: 10.1002/cncr.35175. PubMedAbstract available
MEZA R, Cao P, de Nijs K, Jeon J, et al Assessing the impact of increasing lung screening eligibility by relaxing the
maximum years-since-quit threshold: A simulation modeling study.
Cancer. 2024;130:244-255. PubMedAbstract available
December 2023
TRAN TN, Lee S, Kim HJ, Lee Y, et al Treatment-related cardiovascular events in patients with non-small cell lung
cancer: Evidence from real-world data with a competing risks approach.
Cancer. 2023 Dec 16. doi: 10.1002/cncr.35143. PubMedAbstract available
WANG S, Xie T, Li Y, Guo L, et al Low TP53 variant allele frequency as a biomarker for anti-programmed death
(ligand) 1 monotherapy in lung adenocarcinoma.
Cancer. 2023;129:3873-3883. PubMedAbstract available
ZHAO X, Yang M, Fan J, Wang M, et al Identification of genetically predicted DNA methylation markers associated with
non-small cell lung cancer risk among 34,964 cases and 448,579 controls.
Cancer. 2023 Dec 6. doi: 10.1002/cncr.35130. PubMedAbstract available
Immunotherapy plus stereotactic radiation therapy improves event-free survival in
early-stage non-small cell lung cancer.
Cancer. 2023;129:3680. PubMed
November 2023
GUAN MC, Ding Q, Ning J, Zhu H, et al Metformin as a booster or obstacle of immunotherapy in patients with non-small
cell lung cancer and diabetes mellitus.
Cancer. 2023 Nov 21. doi: 10.1002/cncr.35111. PubMed
LESHEM Y, Dolev Y, Siegelmann-Danieli N, Sharman Moser S, et al Reply to "Metformin as a booster or obstacle of immunotherapy in patients with
non-small cell lung cancer and diabetes mellitus".
Cancer. 2023 Nov 21. doi: 10.1002/cncr.35134. PubMed
GRIESINGER F, Ramagopalan S, Cheung WY, Wilke T, et al Association between treatment and improvements in overall survival of patients
with advanced/metastatic non-small cell lung cancer since 2011: A study in the
United States, Canada, and Germany using retrospective real-world databases.
Cancer. 2023 Nov 7. doi: 10.1002/cncr.35094. PubMedAbstract available
LANDY R, Cheung LC, Young CD, Chaturvedi AK, et al Absolute lung cancer risk increases among individuals with >15 quit-years:
Analyses to inform the update of the American Cancer Society lung cancer
screening guidelines.
Cancer. 2023 Nov 1. doi: 10.1002/cncr.34758. PubMedAbstract available
HENDRICK RE, Smith RA Benefit-to-radiation-risk of low-dose computed tomography lung cancer screening.
Cancer. 2023 Nov 1. doi: 10.1002/cncr.34855. PubMedAbstract available
October 2023
VAN VEGGEL BAMH, van der Wekken AJ, Paats MS, Hendriks LEL, et al A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20
insertion-positive non-small cell lung cancer.
Cancer. 2023 Oct 31. doi: 10.1002/cncr.35090. PubMedAbstract available
MAHAR AL, Biggs K, Hansford RL, Derksen S, et al Stage IV breast, colorectal, and lung cancer at diagnosis in adults living with
intellectual or developmental disabilities: A population-based cross-sectional
study.
Cancer. 2023 Oct 30. doi: 10.1002/cncr.35068. PubMedAbstract available
CHOI E, Luo SJ, Ding VY, Wu JT, et al Risk model-based management for second primary lung cancer among lung cancer
survivors through a validated risk prediction model.
Cancer. 2023 Oct 25. doi: 10.1002/cncr.35069. PubMedAbstract available
PARK S, Kim YJ, Min YJ, Mortimer PGS, et al Biomarker-driven phase 2 umbrella trial: Clinical efficacy of olaparib
monotherapy and combination with ceralasertib (AZD6738) in small cell lung
cancer.
Cancer. 2023 Oct 16. doi: 10.1002/cncr.35059. PubMedAbstract available
FLOREZ N, Kiel L, Meza K, Wei Z, et al Sexual Health Assessment in Women with Lung Cancer study: Sexual health
assessment in women with lung cancer.
Cancer. 2023 Oct 16. doi: 10.1002/cncr.35057. PubMedAbstract available
VAN TUIJL LA, Basten M, Pan KY, Vermeulen R, et al Depression, anxiety, and the risk of cancer: An individual participant data
meta-analysis.
Cancer. 2023;129:3287-3299. PubMedAbstract available
Erratum to "JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in
patients with advanced non-small cell lung cancer".
Cancer. 2023 Oct 13. doi: 10.1002/cncr.35064. PubMed
TAMMEMAGI MC, Cina K, Kitts AKB, Koop D, et al Sensitivity of US Preventive Services Task Force and PLCOm2012 lung cancer
screening eligibility criteria in individuals with lung cancer in South Dakota
self-reporting as Indigenous and non-Indigenous.
Cancer. 2023 Oct 9. doi: 10.1002/cncr.34947. PubMedAbstract available
September 2023
LU S, Guo X, Li Y, Liu H, et al Antiprogrammed death ligand 1 therapy failed to reduce the risk of developing
brain metastases in patients with extensive-stage small cell lung cancer: A
retrospective analysis.
Cancer. 2023 Sep 8. doi: 10.1002/cncr.35003. PubMedAbstract available
TAMMEMAGI MC Time to quit using quit time as a lung cancer screening eligibility criterion.
Cancer. 2023 Sep 1. doi: 10.1002/cncr.34999. PubMed